NRAP

Summary

NRAP (nebulin related anchoring protein, HGNC:7988) is a protein-coding gene on chromosome 10q25.3, encoding Nebulin-related-anchoring protein (Q86VF7). May be involved in anchoring the terminal actin filaments in the myofibril to the membrane and in transmitting tension from the myofibrils to the extracellular matrix.

Predicted to enable actin filament binding activity and muscle alpha-actinin binding activity. Predicted to be involved in cardiac muscle thin filament assembly. Predicted to be located in fascia adherens and muscle tendon junction. Predicted to be active in Z disc.

Source: NCBI Gene 4892 — RefSeq curated summary.

At a glance

• Gene–disease (curated): dilated cardiomyopathy (Strong, ClinGen)
• Clinical variants (ClinVar): 443 total — 2 pathogenic, 11 likely-pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_198060

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7988
Approved symbol	NRAP
Name	nebulin related anchoring protein
Location	10q25.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000197893
Ensembl biotype	protein_coding
OMIM	602873
Entrez	4892

Gene structure

Transcript identifiers

Ensembl transcripts: 76 — 76 protein_coding

ENST00000359988, ENST00000360478, ENST00000369358, ENST00000369360, ENST00000883351, ENST00000883352, ENST00000883353, ENST00000883354, ENST00000883355, ENST00000883356, ENST00000883357, ENST00000883358, ENST00000883359, ENST00000883360, ENST00000883361, ENST00000883362, ENST00000883363, ENST00000883364, ENST00000883365, ENST00000883366, ENST00000883367, ENST00000883368, ENST00000883369, ENST00000883370, ENST00000883371, ENST00000883372, ENST00000945550, ENST00000945551, ENST00000945552, ENST00000945553, ENST00000945554, ENST00000945555, ENST00000945556, ENST00000945557, ENST00000945558, ENST00000945559, ENST00000945560, ENST00000945561, ENST00000945562, ENST00000945563, ENST00000945564, ENST00000945565, ENST00000945566, ENST00000945567, ENST00000945568, ENST00000945569, ENST00000945570, ENST00000945571, ENST00000945572, ENST00000945573, ENST00000945574, ENST00000945575, ENST00000945576, ENST00000945577, ENST00000945578, ENST00000945579, ENST00000945580, ENST00000945581, ENST00000945582, ENST00000945583, ENST00000945584, ENST00000945585, ENST00000945586, ENST00000945587, ENST00000945588, ENST00000945589, ENST00000945590, ENST00000945591, ENST00000945592, ENST00000945593, ENST00000945594, ENST00000945595, ENST00000945596, ENST00000945597, ENST00000945598, ENST00000945599

RefSeq mRNA: 4 — MANE Select: NM_198060 NM_001261463, NM_001322945, NM_006175, NM_198060

CCDS: CCDS73199, CCDS7578, CCDS7579

Canonical transcript exons

ENST00000359988 — 42 exons

Exon	Start	End
ENSE00001188077	113614839	113614946
ENSE00001261874	113605762	113605869
ENSE00001261885	113606178	113606282
ENSE00001261911	113612234	113612431
ENSE00001261999	113592194	113592301
ENSE00001262032	113608414	113608512
ENSE00001262041	113610459	113610563
ENSE00001262778	113614183	113614296
ENSE00001592743	113640227	113640331
ENSE00001630506	113633084	113633188
ENSE00001642561	113621869	113622180
ENSE00001646224	113650037	113650141
ENSE00001647111	113628917	113629021
ENSE00001652323	113657470	113657574
ENSE00001667008	113662679	113662766
ENSE00001677119	113652935	113653039
ENSE00001678417	113620604	113620708
ENSE00001686637	113651803	113651907
ENSE00001693574	113641365	113641472
ENSE00001700565	113634112	113634210
ENSE00001710908	113645825	113645941
ENSE00001711307	113617455	113617553
ENSE00001714490	113629588	113629785
ENSE00001715014	113631857	113631964
ENSE00001716571	113646923	113647027
ENSE00001737976	113623529	113623636
ENSE00001739721	113663352	113663446
ENSE00001754148	113654021	113654125
ENSE00001775177	113650438	113650545
ENSE00001777613	113642934	113643038
ENSE00001795267	113631509	113631610
ENSE00001802729	113615712	113615816
ENSE00001820208	113663811	113664041
ENSE00002468570	113604609	113604920
ENSE00002476564	113624826	113624930
ENSE00002481899	113595623	113595727
ENSE00002489081	113626047	113626145
ENSE00002504515	113597086	113597184
ENSE00002510093	113589666	113589797
ENSE00002521283	113590578	113590889
ENSE00002533044	113597969	113598073
ENSE00003287753	113588714	113589079

Expression profiles

Bgee: expression breadth ubiquitous, 157 present calls, max score 99.85.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 6.2725 / max 2211.6433, expressed in 54 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
111459	6.2478	54
111453	0.0246	10

Top tissues by expression

279 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	99.85	gold quality
hindlimb stylopod muscle	UBERON:0004252	99.60	gold quality
gastrocnemius	UBERON:0001388	99.56	gold quality
gluteal muscle	UBERON:0002000	99.56	gold quality
apex of heart	UBERON:0002098	99.49	gold quality
body of tongue	UBERON:0011876	99.48	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	99.32	gold quality
triceps brachii	UBERON:0001509	98.95	gold quality
diaphragm	UBERON:0001103	98.87	gold quality
biceps brachii	UBERON:0001507	98.61	gold quality
cardiac ventricle	UBERON:0002082	98.49	gold quality
heart left ventricle	UBERON:0002084	98.49	gold quality
heart right ventricle	UBERON:0002080	97.98	gold quality
skeletal muscle tissue	UBERON:0001134	97.91	gold quality
vastus lateralis	UBERON:0001379	97.76	gold quality
right atrium auricular region	UBERON:0006631	97.65	gold quality
cardiac atrium	UBERON:0002081	97.63	gold quality
left ventricle myocardium	UBERON:0006566	97.57	gold quality
muscle of leg	UBERON:0001383	97.53	gold quality
muscle organ	UBERON:0001630	97.50	gold quality
quadriceps femoris	UBERON:0001377	96.90	gold quality
cardiac muscle of right atrium	UBERON:0003379	96.88	gold quality
myocardium	UBERON:0002349	96.27	gold quality
deltoid	UBERON:0001476	95.94	gold quality
tibialis anterior	UBERON:0001385	95.17	silver quality
muscle tissue	UBERON:0002385	93.57	gold quality
heart	UBERON:0000948	92.97	gold quality
tongue	UBERON:0001723	92.32	gold quality
vena cava	UBERON:0004087	90.77	gold quality
pharyngeal mucosa	UBERON:0000355	90.02	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.62

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

13 targeting NRAP, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-4498	99.47	67.42	2360
HSA-MIR-3160-5P	99.28	69.07	1938
HSA-MIR-3191-5P	99.24	66.52	1722
HSA-MIR-6744-3P	99.22	64.41	972
HSA-MIR-4757-5P	99.12	64.51	981
HSA-MIR-6764-3P	98.44	67.64	1153
HSA-MIR-6824-3P	98.44	67.62	1154
HSA-MIR-4299	98.28	66.96	850
HSA-MIR-3664-3P	97.85	67.62	1452
HSA-MIR-4456	97.50	64.88	1678

Literature-anchored findings (GeneRIF, showing 3)

• Highly conserved and exclusively expressed in cardiac and skeletal muscle. Candidate cause for cardiac and skeletal myopathies (PMID:12789664)
• Loss-of-function mutation in NRAP gene is associated with dilated cardiomyopathy. (PMID:28611399)
• Biallelic loss-of-function in NRAP is a cause of recessive dilated cardiomyopathy. (PMID:33534821)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	nrap	ENSDARG00000009341
mus_musculus	Nrap	ENSMUSG00000049134
rattus_norvegicus	Nrap	ENSRNOG00000016714
drosophila_melanogaster	Hil	FBGN0050147
caenorhabditis_elegans		WBGENE00003089

Paralogs (4): LASP1 (ENSG00000002834), NEBL (ENSG00000078114), KY (ENSG00000174611), NEB (ENSG00000183091)

Protein

Protein identifiers

Nebulin-related-anchoring protein — Q86VF7 (reviewed: Q86VF7)

All UniProt accessions (2): A0A0A0MRM2, Q86VF7

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in anchoring the terminal actin filaments in the myofibril to the membrane and in transmitting tension from the myofibrils to the extracellular matrix.

Subunit / interactions. Interacts with actin, alpha-actinin, KLHL41, TLN1 and VCL. Interacts with CSRP3.

Tissue specificity. Expressed in cardiac and skeletal muscle.

Isoforms (4)

UniProt ID	Names	Canonical?
Q86VF7-1	1	yes
Q86VF7-2	2
Q86VF7-3	3
Q86VF7-4	4

RefSeq proteins (4): NP_001248392, NP_001309874, NP_006166, NP_932326* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000900	Nebulin_repeat	Repeat
IPR001781	Znf_LIM	Domain
IPR013998	Nebulin-like	Family
IPR055297	NEBU/NEBL	Family

Pfam: PF00412, PF00880

UniProt features (90 total): repeat 44, sequence variant 20, sequence conflict 19, splice variant 2, chain 1, domain 1, region of interest 1, compositionally biased region 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86VF7-F1	51.98	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 1081

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 98 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_DN, FREAC2_01, GOBP_MUSCLE_TISSUE_DEVELOPMENT, GOBP_STRIATED_MUSCLE_CELL_DIFFERENTIATION, GOBP_CARDIAC_MYOFIBRIL_ASSEMBLY, TGACCTY_ERR1_Q2, GOBP_CELLULAR_COMPONENT_ASSEMBLY_INVOLVED_IN_MORPHOGENESIS, GOBP_MUSCLE_STRUCTURE_DEVELOPMENT, GOBP_ACTIN_FILAMENT_ORGANIZATION, GOBP_CARDIAC_MUSCLE_CELL_DIFFERENTIATION, GOBP_ACTOMYOSIN_STRUCTURE_ORGANIZATION, HNF4_01, GOBP_ORGANELLE_ASSEMBLY, PPAR_DR1_Q2, TATA_C

GO Biological Process (1): cardiac muscle thin filament assembly (GO:0071691)

GO Molecular Function (6): actin binding (GO:0003779), vinculin binding (GO:0017166), metal ion binding (GO:0046872), actin filament binding (GO:0051015), muscle alpha-actinin binding (GO:0051371), protein binding (GO:0005515)

GO Cellular Component (5): fascia adherens (GO:0005916), muscle tendon junction (GO:0005927), Z disc (GO:0030018), cytoplasm (GO:0005737), myofibril (GO:0030016)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoskeletal protein binding	2
cellular anatomical structure	2
actin filament organization	1
cardiac myofibril assembly	1
cation binding	1
actin binding	1
protein-containing complex binding	1
alpha-actinin binding	1
binding	1
cell-cell junction	1
intercalated disc	1
cell-substrate junction	1
I band	1
intracellular anatomical structure	1
contractile muscle fiber	1

Protein interactions and networks

STRING

836 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NRAP	TRIM63	Q969Q1	565
NRAP	MYOT	Q9UBF9	518
NRAP	NEB	P20929	478
NRAP	KLHL41	O60662	475
NRAP	XIRP1	Q702N8	463
NRAP	DNAJC28	Q9NX36	455
NRAP	RYR2	Q92736	430
NRAP	TCAP	O15273	423
NRAP	MYO10	Q9HD67	416
NRAP	ZYX	Q15942	415
NRAP	CLMN	Q96JQ2	409
NRAP	ZNF622	Q969S3	409
NRAP	TTN	Q8WZ42	406
NRAP	XIRP2	A4UGR9	384
NRAP	TRIM54	Q9BYV2	373

IntAct

10 interactions, top by confidence:

A	B	Type	Score
ACTN2	CSRP3	psi-mi:“MI:0914”(association)	0.690
KLHL41	NRAP	psi-mi:“MI:0915”(physical association)	0.690
KLHL41	NRAP	psi-mi:“MI:0407”(direct interaction)	0.690
ACTN2	NRAP	psi-mi:“MI:0407”(direct interaction)	0.520
CSRP3	NRAP	psi-mi:“MI:0407”(direct interaction)	0.440
NRAP	MAGT1	psi-mi:“MI:0915”(physical association)	0.400
KLHL41	NRAP	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (16): NRAP (FRET), NRAP (Two-hybrid), KLHL41 (Affinity Capture-Western), NRAP (Affinity Capture-Western), MAGT1 (Proximity Label-MS), NRAP (Two-hybrid), NRAP (Reconstituted Complex), VCL (Reconstituted Complex), YWHAE (Cross-Linking-MS (XL-MS)), AGR2 (Cross-Linking-MS (XL-MS)), DNAJB1 (Cross-Linking-MS (XL-MS)), NRAP (Cross-Linking-MS (XL-MS)), NRAP (Cross-Linking-MS (XL-MS)), NRAP (Cross-Linking-MS (XL-MS)), NRAP (Two-hybrid)

ESM2 similar proteins: A6ZM93, A8WL28, B3LLS9, B5VPF9, C5DGV3, C5DX05, C7GL88, C8ZEN7, E7LYB2, H2KYS8, J7M799, O02828, O17389, O76041, O85041, P0CU45, P0CU46, P0CU48, P0CU50, P14317, P27321, P29172, P34549, P37397, P37801, P37806, P49710, P57786, P91859, P91927, Q01406, Q05050, Q09936, Q0II04, Q10195, Q15417, Q18879, Q24211, Q31HD7, Q32L92

Diamond homologs: B0KYV5, D4A1F2, F1LR10, F1MF74, F1QH17, F1QWK4, F1RA39, F6QZ15, G3MWR8, G5EF51, O04193, O60952, O77506, O80839, O94851, P21291, P29675, P36201, P47875, P50460, P50461, P50462, P50463, P52943, P53777, P67966, P67967, P97314, P97315, Q05158, Q0E908, Q0VFX8, Q14847, Q16527, Q1ECF5, Q1LZA7, Q32LE9, Q3B7M5, Q3MHY1, Q4KM31

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

443 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	11
Uncertain significance	236
Likely benign	72
Benign	100

Top pathogenic / likely-pathogenic (13)

Variant ID	HGVS	Classification
1711905	NM_198060.4(NRAP):c.400_407del (p.Cys134fs)	Pathogenic
2579962	NM_198060.4(NRAP):c.3109C>T (p.Arg1037Ter)	Pathogenic
1699323	NM_198060.4(NRAP):c.3301-2A>G	Likely pathogenic
2080715	NM_198060.4(NRAP):c.3604-2A>C	Likely pathogenic
2629310	NM_198060.4(NRAP):c.1843-2A>G	Likely pathogenic
3346392	NM_198060.4(NRAP):c.619del (p.Val207fs)	Likely pathogenic
3372657	NM_198060.4(NRAP):c.4219C>T (p.Gln1407Ter)	Likely pathogenic
3894990	NM_198060.4(NRAP):c.3099G>A (p.Trp1033Ter)	Likely pathogenic
3895320	NM_198060.4(NRAP):c.4197G>A (p.Trp1399Ter)	Likely pathogenic
4278443	NM_198060.4(NRAP):c.2244+1G>A	Likely pathogenic
4820403	NM_198060.4(NRAP):c.994-1G>T	Likely pathogenic
4820486	NM_198060.4(NRAP):c.4206del (p.Ala1403fs)	Likely pathogenic
4820505	NM_198060.4(NRAP):c.3078+1G>T	Likely pathogenic

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

11556 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:113617484:C:G	A982P	0.995
10:113617518:A:C	F970L	0.995
10:113617518:A:T	F970L	0.995
10:113617520:A:G	F970L	0.995
10:113634141:C:G	A500P	0.995
10:113617543:C:G	R962P	0.992
10:113624843:C:G	A778P	0.991
10:113624855:C:G	A774P	0.990
10:113626110:G:C	F727L	0.989
10:113626110:G:T	F727L	0.989
10:113626112:A:G	F727L	0.989
10:113634129:C:G	A504P	0.988
10:113663429:A:C	C30W	0.985
10:113646952:C:G	A322P	0.984
10:113663413:A:G	C36R	0.984
10:113615715:A:C	S1025R	0.983
10:113615715:A:T	S1025R	0.983
10:113615717:T:G	S1025R	0.983
10:113617544:G:T	R962S	0.983
10:113628979:A:G	W695R	0.983
10:113628979:A:T	W695R	0.983
10:113663411:G:C	C36W	0.983
10:113592197:A:C	S1547R	0.982
10:113592197:A:T	S1547R	0.982
10:113592199:T:G	S1547R	0.982
10:113634115:A:C	S508R	0.982
10:113634115:A:T	S508R	0.982
10:113634117:T:G	S508R	0.982
10:113663431:A:G	C30R	0.982
10:113617519:A:G	F970S	0.981

dbSNP variants (sampled 300 via entrez): RS1000087445 (10:113603174 G>A), RS1000130512 (10:113637848 G>A), RS1000198500 (10:113608324 G>A,T), RS1000223466 (10:113602117 A>G,T), RS1000249683 (10:113609375 A>T), RS1000286707 (10:113654602 A>G), RS1000292473 (10:113644649 A>G), RS1000313250 (10:113648780 T>G), RS1000349931 (10:113626776 G>A,C,T), RS1000442027 (10:113654340 A>T), RS1000477956 (10:113609778 G>A), RS1000488496 (10:113614414 G>A), RS1000534581 (10:113591634 T>C,G), RS1000598582 (10:113649043 G>C), RS1000622500 (10:113661651 C>G,T)

Disease associations

OMIM: gene MIM:602873 | disease phenotypes: MIM:618225

GenCC curated gene-disease

Disease	Classification	Inheritance
dilated cardiomyopathy	Strong	Autosomal recessive

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
dilated cardiomyopathy	Strong	AR

Mondo (2): dilated cardiomyopathy (MONDO:0005021), mitochondrial complex I deficiency, nuclear type 4 (MONDO:0032609)

Orphanet (1): Dilated cardiomyopathy (Orphanet:217604)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0001644	Dilated cardiomyopathy

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D002311	Cardiomyopathy, Dilated	C14.280.195.160; C14.280.238.070; C16.320.488.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Doxorubicin	decreases expression	4
Benzo(a)pyrene	affects methylation, increases expression, increases methylation	3
Daunorubicin	decreases expression	2
Mitoxantrone	decreases expression	2
terbufos	increases methylation	1
sodium arsenite	decreases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
S-(1,2-dichlorovinyl)cysteine	decreases reaction, increases expression, decreases expression	1
CGP 52608	affects binding, increases reaction	1
2,7-dihydroxynaphthalene	decreases expression	1
incobotulinumtoxinA	decreases expression	1
Resveratrol	decreases expression, affects cotreatment	1
Sunitinib	decreases expression	1
Fonofos	increases methylation	1
Endosulfan	decreases expression	1
Etoposide	decreases expression	1
Lipopolysaccharides	increases expression, decreases reaction	1
Methapyrilene	increases methylation	1
Parathion	increases methylation	1
Plant Extracts	affects cotreatment, decreases expression	1
Dronabinol	decreases expression	1
Aflatoxin B1	decreases methylation	1
Cadmium Chloride	increases expression	1
Okadaic Acid	increases expression	1
Copper Sulfate	increases expression	1

Clinical trials (associated diseases)

158 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00374465	PHASE4	UNKNOWN	Therapy With Verapamil or Carvedilol in Chronic Heart Failure
NCT01293903	PHASE4	COMPLETED	Study of Qiliqiangxin Capsule to Treat Dilated Cardiomyopathy
NCT01557140	PHASE4	COMPLETED	A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy
NCT01917149	PHASE4	COMPLETED	Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy
NCT02115581	PHASE4	COMPLETED	Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy
NCT06236022	PHASE4	RECRUITING	The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
NCT00333827	PHASE3	COMPLETED	Cell Therapy In Dilated Cardiomyopathy
NCT00505154	PHASE3	COMPLETED	Effect of Rosuvastatin on Left Ventricular Remodeling
NCT01223703	PHASE3	COMPLETED	PUFAs and Left Ventricular Function in Heart Failure
NCT01583114	PHASE3	TERMINATED	PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy and ACE Inhibitors
NCT01914081	PHASE3	UNKNOWN	Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside
NCT02989181	PHASE3	UNKNOWN	Continues Positive Airway Pressure Treatment for Patients With Dilated Cardiomyopathy and Obstructive Sleep Apnea
NCT03439514	PHASE3	TERMINATED	A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation
NCT05237323	PHASE3	COMPLETED	Micophenolate Mofetil Versus Azathioprine in Myocarditis
NCT05849766	PHASE3	COMPLETED	Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction
NCT06250257	PHASE3	RECRUITING	Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age
NCT00629018	PHASE2	COMPLETED	Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy
NCT00629096	PHASE2	COMPLETED	Intracoronary Infusion of Autologous Bone Marrow Cells for Treatment of Idiopathic Dilated Cardiomyopathy
NCT00765518	PHASE2	COMPLETED	Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)
NCT00847964	PHASE2	COMPLETED	Safety and Feasibility of Algisyl-LVR™ as a Method of Left Ventricular Restoration in Patients With DCM Undergoing Open-heart Surgery
NCT01020968	PHASE2	COMPLETED	Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy
NCT01302171	PHASE2	COMPLETED	Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy
NCT01350310	PHASE2	COMPLETED	Safety and Efficacy Study of Intramyocardial Stem Cell Therapy in Patients With Dilated Cardiomyopathy
NCT02133911	PHASE2	COMPLETED	A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy
NCT03071653	PHASE2	SUSPENDED	Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study
NCT03572660	PHASE2	ACTIVE_NOT_RECRUITING	Use of Bone Marrow Derived Stem Cell and G-CSF With Circulatory Assistance in the Treatment of DCM
NCT03775070	PHASE2	COMPLETED	Simvastatin Therapy in Patients With Dilated Cardiomyopathy.
NCT04405804	PHASE2	UNKNOWN	Early Administration of Ivabradine in Children With Heart Failure
NCT05410873	PHASE2	COMPLETED	Examining the Effects of Mitochondrial Oxidative Stress in DCM
NCT06632834	PHASE2	RECRUITING	Outcome-targeted Therapy: Principle and Outcome Evaluation: Clinical Study and Phenotype-genotype Correlation
NCT00585546	PHASE1	TERMINATED	Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure
NCT02293603	PHASE1	UNKNOWN	Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC)
NCT03062956	PHASE1	COMPLETED	A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491
NCT03129568	PHASE1	COMPLETED	Transcoronary Infusion of Cardiac Progenitor Cells in Pediatric Dilated Cardiomyopathy
NCT04982081	PHASE1	UNKNOWN	Treating Congestive HF With hiPSC-CMs Through Endocardial Injection
NCT06381466	PHASE1	TERMINATED	A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.
NCT06464588	PHASE1	RECRUITING	A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)
NCT06902896	PHASE1	COMPLETED	Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy
NCT07137338	PHASE1	RECRUITING	A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy
NCT07241104	PHASE1	RECRUITING	A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy